Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...

Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine, becoming the first new class of pain ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

San Francisco-based Rad AI, which develops generative AI (GenAI) tools to improve radiology workflows, has raised $60 million ...

Robert F Kennedy Jr's first confirmation hearing was a fractious affair, marked by tough questions about his prior ...

President Trump will continue to pursue the policy of Medicare pricing negotiation introduced by former President Biden's ...

The growing use of AI has opened new avenues for healthcare marketers, revolutionising how they approach new initiatives.

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

The industry is grappling with significant market shifts amidst emerging technologies and changing demands. Companies are now ...

Shares in 23andMe are currently trading at around $3.40, giving it a valuation of just under $82 million. The company went ...